Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 646 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LINKED Clear all
Recruiting No phase listed Observational

ExoLuminate Study for Early Detection of Pancreatic Cancer

NCT05625529
View directory record Official record
Conditions
Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
Biological Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Caregiver-Guided Pain Management Training in Palliative Care

NCT02430467
View directory record Official record
Conditions
Advanced Cancer
Interventions
Caregiver-guided pain management training (CG-PMT), Enhanced treatment-as-usual (TAU)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Early Phase 1 Interventional

Burosumab for CSHS

NCT03993821
View directory record Official record
Conditions
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Interventions
Burosumab
Drug
Lead sponsor
Laura Tosi
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

NCT00621452
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
therapeutic autologous lymphocytes, cyclophosphamide, aldesleukin, polymerase chain reaction, gene rearrangement analysis, lymph node biopsy, genetically engineered lymphocyte therapy, bone marrow aspiration, flow cytometry, laboratory biomarker analysis, enzyme-linked immunosorbent assay
Biological · Drug · Genetic + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Sep 4, 2026, 4:08 PM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

NCT02624258
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
CD19 RNA redirected autologous T-cells (RNA CART19 cells)
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 24 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 2Phase 3 Interventional

A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

NCT03231878
View directory record Official record
Conditions
Adrenoleukodystrophy
Interventions
MIN-102, Placebos
Drug
Lead sponsor
Minoryx Therapeutics, S.L.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Not listed Not applicable Interventional

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

NCT05846113
View directory record Official record
Conditions
Kidney Diseases
Interventions
Renasight
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Anchorage, Alaska • Tucson, Arizona • Granada Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hybrid STTR Intervention for Heterosexuals: Anonymous Testing and Confidential Care Linkage

NCT02421159
View directory record Official record
Conditions
HIV/AIDS
Interventions
Seek and Test Phase, Treat and Retain Phase
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 60 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Not applicable Interventional

Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors

NCT05364450
View directory record Official record
Conditions
Breast Neoplasm, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast, Cancer of Breast, Mammary Neoplasms, Human, Human Mammary Carcinoma, Malignant Tumor of Breast, Mammary Cancer, Mammary Carcinoma, Human, Anxiety, Fear
Interventions
Enhanced Usual Care, Acceptance Commitment Therapy, Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 4, 2026, 4:08 PM EDT
Terminated Phase 1 Interventional

CART-38 in Adult AML and MM Patients

NCT05442580
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
Interventions
3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells, 3x10(7) CART-38 cells, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

NCT00594932
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritis
Interventions
mycophenolate mofetil, placebo
Drug · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
14 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 4, 2026, 4:08 PM EDT
Withdrawn No phase listed Observational

Male Stress Urinary Incontinence and Sexual Health

NCT01379378
View directory record Official record
Conditions
Prostate Cancer
Interventions
Artificial urinary sphincter, InVance Sling, AdVance Sling, Virtue Sling, Contigen
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 1 Interventional

A Study of KRN23 in X-linked Hypophosphatemia

NCT00830674
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
Placebo, KRN23
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 4, 2026, 4:08 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of VG712 in Patients With Mycosis Fungoides

NCT07529405
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
VG712, Mogamulizumab
Drug
Lead sponsor
Virogen Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Terminated Phase 1 Interventional

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

NCT05605522
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
Interventions
[225]-FPI-2059, [111In]-FPI-2058
Drug
Lead sponsor
3B Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Birmingham, Alabama • Duarte, California • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Not applicable Interventional

MI-BP: mHealth to Improve Blood Pressure Control

NCT02955537
View directory record Official record
Conditions
Hypertension
Interventions
MI-BP
Other
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 70 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 4, 2026, 4:08 PM EDT
Active, not recruiting No phase listed Observational

X-linked Hypophosphatemia Disease Monitoring Program

NCT03651505
View directory record Official record
Conditions
X-linked Hypophosphatemia, Hypophosphatemic Rickets
Interventions
No intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 2Phase 3 Interventional

A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results

NCT02355080
View directory record Official record
Conditions
Substance-related Disorders
Interventions
On-site bundled rapid HIV/HCV testing, Standard of care (SOC)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 4, 2026, 4:08 PM EDT
Not yet recruiting No phase listed Observational

Creating Linked Inpatient CGM for Kids

NCT06899503
View directory record Official record
Conditions
Diabetes, Continuous Glucose Monitoring System
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Weeks to 24 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Active, not recruiting Phase 1 Interventional Results available

ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM

NCT05283109
View directory record Official record
Conditions
Glioma, Malignant
Interventions
Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, Hiltonol
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Recruiting Not applicable Interventional

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

NCT07376772
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Interventions
wearable focal vibration therapy
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

eCEASE to Support Treatment for Parental Tobacco Use

NCT04974736
View directory record Official record
Conditions
Tobacco Smoking, Second Hand Tobacco Smoke, Smoking Cessation
Interventions
iEHR + Navigator
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Responses in PIDD Subjects

NCT05321407
View directory record Official record
Conditions
X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
6 Months and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 4, 2026, 4:08 PM EDT
Completed Phase 3 Interventional Results available

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

NCT05295732
View directory record Official record
Conditions
Ichthyosis
Interventions
TMB-001, Matching Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
6 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 4, 2026, 4:08 PM EDT